Davion Healthcare Plc (DAVI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DAVI
- Company Davion Healthcare Plc
- Price $1.49
- Changes Percentage -11.31
- Change -0.19
- Day Low $1.46
- Day High $1.68
- Year High $12.3
- Year Low $10.11
- Market Cap $291,250,000
- Price Avg 50 EMA (D) $10.11
- Price Avg 200 EMA (D) $10.11
- Exchange NASDAQ
- Volume 558,417
- Average Volume 2,810
- Open $1.68
- Previous Close $1.68
- EPS 0
- PE 0.00
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $25,000,000
Company brief: DAVION HEALTHCARE PLC (DAVI )
- Healthcare
- Medical - Devices
- Glenn Williams
- https://www.davionhealthcare.com
- IE
- N/A
- 10-22-2026
- IE000GVCI8S8
Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary. It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.